Status:

COMPLETED

Zoledronate for Osteopenia in Pediatric Crohn's

Lead Sponsor:

McGill University Health Centre/Research Institute of the McGill University Health Centre

Collaborating Sponsors:

Crohn's and Colitis Foundation

Conditions:

Crohn's Disease

Osteopenia

Eligibility:

All Genders

6-18 years

Phase:

PHASE3

Brief Summary

Background: * Up to 30% of children and adolescents with Crohn's disease have decreased bone strength, or decrease bone density, called osteopenia. * Bisphosphonates are a group of drugs that have be...

Detailed Description

* This study is recruiting 40 children and adolescents, aged 6 to 18, who have a proven abnormal bone density as measured on a special type of x-ray called a DEXA-scan. * Participants are allocated at...

Eligibility Criteria

Inclusion

  • patients aged 6 to 18,
  • diagnosed with Crohn's disease with osteopenia,
  • a minimum of 6 months of adequate calcium and vitamin D intake. (Osteopenia was defined for the purposes of this study as: Z-score lumber spine BMD by DEXA of -2.0 or less, or -1.5 and a risk factor (either steroid use for 6 months or more or decrease of 0.5 z-score in the preceding 12 months).)

Exclusion

  • renal dysfunction,
  • insufficient calcium or vitamin D intake,
  • current medication or condition affecting bone metabolism,
  • documented fracture, previously diagnosed bone disease,
  • documented intolerance/hypersensitivity to bisphosphonates,
  • previous treatment with bisphosphonates within the last 6 months.

Key Trial Info

Start Date :

September 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2008

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT00798473

Start Date

September 1 2004

End Date

November 1 2008

Last Update

November 26 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

McGill University Health Center - Montreal Children's Hospital

Montreal, Quebec, Canada, H3H 1P3